Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's Cash Challenge, Gilead's Life After HCV, Pfizer's Pricing Gripe

Executive Summary

Held in Boston, Sept. 7-8, the Wells Fargo Healthcare Conference saw the likes of Gilead Sciences, Johnson and Johnson and Pfizer discuss their strategies for 2017, pipeline highlights and biggest challenges. We pick out five key pointers from industry leaders.

You may also be interested in...

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.

JnJ Not Sweating Remicade Biosimilar Approval

Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.

Deals Shaping Medtech And Diagnostics, September 2021

Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts